In the 4T1 mouse model, although tumor cells displayed few responses to the anti-PD1 antibody treatment, it had made great regression of tumor burden in the anti-PD1 combination with JK184 therapy (p < 0.001) (Fig. 6B). Here, PDCD1 is linked to neoplasm.